As demand for a healthy liver rises, the current market value for liver transplants is likely to reach US$ 1,409.8 million. The market is expected to be worth around US$ 2,653.4 million by 2033. The market for liver transplants is estimated to record a growth of 6.5% during the forecast period.
Key Market Highlights
Shortage of Donor Livers is Boosting the Machine Perfusion Technique
Machine perfusion techniques are becoming popular in clinical practice as they preserve organs and are suitable for reconditioning. The technology is widely used for the defatting of steatotic livers and gene therapy. It also avoids the needless wastage of organs and improves the quality of marginal livers.
A study published on new therapy and drug trials in 2023 stated that out of 10,000 people who needed a liver transplant, only around 5,000 managed to get one. Therefore, liver perfusion, which includes warm and cold perfusion techniques, is making a difference in clinical trials for liver transplants.
Bile Duct Cancer and Alcoholic Liver Disease Increased the Requirement of Liver Transplant
Excess consumption of alcohol, which is also the common cause of cirrhosis and hepatitis C, leads to irreversible liver failure. According to a survey conducted by NIDDK, alcoholic-related liver disease is most common in the United States, where 1 out of 400 people is diagnosed with cirrhosis.
As per the National Institute of Cancer, patients with cholangiocarcinoma or bile duct cancer are more prone to liver transplant. However, according to the researchers at NYU Langone Transplant Institute, patients with early liver cancer have a higher liver transplant success rate. In 2020, around 905,600 people were diagnosed with liver cancer, and men are more likely to be diagnosed with the disease than women.
| Attributes | Key Statistics |
|---|---|
| Expected Base Year Value (2023) | US$ 1,409.8 million |
| Anticipated Forecast Value (2033) | US$ 2,653.4 million |
| Estimated Growth (2023 to 2033) | 6.5% CAGR |
Usually, the liver is procured from deceased donors, but advancements in medical technology have made it possible to obtain a liver from a living person as well. Being one of the most replaced organs after the kidney, the demand for the liver has increased substantially over the years.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
In the comparative outlook between the liver transplant market from 2018 to 2022 and the forecast projected for 2023 to 2033, the disease has become the third most common globally.
As per the liver transplant market analysis, the industry is poised to attain revenue of about US$ 2,653.4 million by 2033. The market recorded a growth of
| Attributes | Details |
|---|---|
| Market Size (2022) | US$ 1,340.3 million |
| CAGR (2017 to 2022) | 4.2% |
According to Cancer.Net, liver cancer was stabilized between 2016 and 2020, although surging acute liver failure and autoimmune hepatitis are damaging the liver, leading to transplants. By the end of 2023, around 19,000 men in the United States may be diagnosed with liver cancer.
Globally, the demand for organs greatly outpaces the supply. The same is true for liver transplantation as well. One of the key concerns regarding this is that many patients who need liver transplants die on the waiting list.
In the United States alone, over 8,000 liver transplants are performed annually, with a survival rate of 90 percent. The only concern is the waiting period, which is about 15 months. Many studies in the medical field aim to bridge the gap between donor availability and the requirement for a healthy liver all around the world.
Factors Driving the Demand for Liver Transplantation
Factors Restraining the Growth of Liver Transplantation Market
| Attributes | Details |
|---|---|
| North America Market Share (2022) | 29.2% |
| Europe Market Share (2022) | 20.7% |
The highly urban lifestyle, which includes excessive alcohol consumption, junk food, and exposure to toxins, plays an important role in the liver's health. According to liver transplantation statistics, the North America liver transplantation market showed a 29.2% share in 2022.
Better medical facilities coupled with robust support from the government when it comes to reimbursement policies are vital reasons for the market expansion in this region.
Several countries are showing promising demand in the European liver transplant market. Of the total global share, over 20% of liver transplants are carried out in Europe, making it one of the core regions in this industry.
Advanced medical facilities in developed nations and better financial conditions for people residing in these nations contribute massively to the growth of the liver transplantation sector.
Principal Consultant
The below highlights the market revenue by key countries. The United States is leading in the market, with a growth of 25.8%. The next leading market is China, with a CAGR of 7.7 in 2022, followed by India. FMI estimates that these top five markets represent an overwhelming regional opportunity out of the other countries covered in reports.
As per the liver transplantation market analysis by FMI, The United States emerged as a significant market due to organ transplant surgeries, the United States liver transplant market recorded a growth of 25.8% in 2022.
| Country | The United States |
|---|---|
| Value Share in 2022 | 25.8% |
Research and development for liver transplant devices, both by private and public organizations, are some prominent factors involved in the betterment of the liver transplantation market in the United States.
For instance, OrganOx metra, developed by OrganOx Limited, is an automated transportable device for normothermic organ perfusion. The device makes the liver functional throughout the preservation period by continuously perfusing it with oxygenated blood, nutrients, and medications at a normal body temperature.
The market share of liver transplants in Germany was around 5.3% in 2022. Currently securing the first market position in terms of growth, this standing is anticipated to continue in the foreseeable future
| Country | Germany |
|---|---|
| Value Share in 2022 | 5.3% |
To fasten the liver transplantation process by cutting down long waiting lines and increasing transplantation rates, many European countries have started cooperating with transnational organizations like Eurotransplant, Scandiatransplant, and the Southern Alliance for Transplantation. Transnational organ-sharing companies oversee and regulate all the liver transplantation procedures within their member nations, which fuels an efficient, fast, and swift process.
Several strategies have been implemented by the Department of Surgery and Transplantation in Germany to expand the pool of donors for orthotopic LT. Significant advancement has been made to organ preservation, which includes hypothermic oxygenated machine perfusion (HOPE) and hypothermic and normothermic, among others.
The market share of liver transplants in Japan was around 5.2% in 2022. The market is expected to grow substantially due to the country's surging awareness of organ transplantation.
| Country | Japan |
|---|---|
| Value Share in 2022 | 5.2% |
Awareness regarding liver donation is increasing day by day, which positively affects the market in Japan. According to the Liver Transplantation Society, more than 9,000 liver transplant was carried out in Japan in around 67 institutions in 2017.
Government programs fuel large-scale transplantation schemes for the residents who deal with such diseases. With the entry of private players in the market, the country is all set to experience tremendous growth in the liver transplant surgery instrument market, which may elevate market revenue in the years to come.
Evolving technology to optimize organ preservation is increasing the market size of liver transplants in China. The market for liver transplants registered a growth of 7.7% in 2022.
| Country | China |
|---|---|
| Value Share in 2022 | 7.7% |
The risk of technology-related and logistics hurdles is the key concern for liver transplant and preservation. Currently, the orthotopic liver transplantation technique is widely incorporated by surgeons in China. However, the country has witnessed a bar of growth in living donors over the past few years.
According to a report, more than 50,000 people in China were diagnosed with end-stage liver diseases who needed liver transplants in 2020. Moreover, Hepatocellular carcinoma is a key indication for transplant, where 40% of liver grafts were transplanted to patients with liver cancer.
The liver transplant market in India recorded a share of 6.3% in 2022. The market is expected to rise due to an increase in end-to-end ductal anastomosis for liver transplants and IBDI.
| Country | India |
|---|---|
| Value Share in 2022 | 6.3% |
According to the report published by NOTTO in 2022, living donor liver transplant is broadly adopted in India, around 85%. The percentage of LDLT is higher in the country due to a lack of preservation techniques such as machine perfusion technology.
The population that requires liver transplantation in India is 80% male, who suffers from HCC, decompensated cirrhosis, acute-on-chronic liver failure, and ALF. Alcoholic-related liver disease is a key cause of LT in India due to heavy drinkers and autoimmune diseases.
The rising prevalence of hepatitis A, B, and C due to passive lifestyles is the leading cause of acute liver failure across the globe. Liver transplantation surgery has shown a promising share of 61.1% based on the treatment type.
| Top Segment | Liver Transplantation Surgery |
|---|---|
| Market Share | 61.1% |
The promising liver transplantation success rate is also why more and more people trust these surgeries. According to an analysis, around 8,000 liver transplants are carried out every year, with a success rate of 85% or more. The availability of robust medical infrastructure, skilled surgeons, and government support have all contributed to improving the liver transplantation surgery market.
Liver transplants can be carried out in hospitals, ambulatory surgical centers, and adult liver transplantation centers. By end-use, the liver transplantation market is fragmented in the same centers, with hospitals holding a leading share.
| Top Segment | Hospitals |
|---|---|
| Market Share | 51.2% |
In developed countries, hospitals are more robust and provide excellent services before and after liver transplantation procedures. A lot of blood is lost during the surgery, making the arrangement of blood more feasible for hospitals as compared to other clinical units.
According to the forecast, 51% of liver transplantation surgeries are carried out in hospitals, which may account for more than half of the global revenue generated in this industry.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Many start-up companies in the Western market are bringing innovative medical devices that can ease the process of transplantation and give more advantages to the donor as well as the recipient.
Several European companies are at the forefront of changing how the liver donated by living as well as deceased donors is preserved in the time between liver transplantation procedures. Usually, the shelf-life of the liver once taken out of the body is 12 hours, after which the liver becomes unusable. Efforts are being made to elongate this period for the patient's convenience.
HepaTx, a United States-based company, develops therapies to treat liver disease using regenerative medicine. The company is developing new types of treatments based on stem cells to bring new therapies to patients with late-stage liver disease as an alternative to liver transplants. According to the company's data, only one out of the thirty-three patients who need liver transplants successfully gets the organ on time. Despite millions of dollars spent by the government in the healthcare sector, much disparity is observed between the donor and patient numbers.
Recent Developments in Liver Transplantation
Key Market Players
The market value of liver transplantation is estimated to be US$ 1,409.8 million.
Excessive alcohol abuse, drug intoxication, and unhealthy eating habits.
China, Japan, and India dominate the liver transplant industry in Asia Pacific.
Germany recorded a market share of 5.3% in 2022.
North America is expected to be the most opportunistic, accumulating 29.2% of the share in 2022.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033
5.3.1. Surgery
5.3.2. Post-Surgery Anti-Rejection Treatment
5.3.3. Cyclosporine
5.3.4. Tacrolimus
5.3.5. Sirolimus
5.3.6. Prednisone
5.3.7. Azathioprine
5.3.8. Mycophenolate Mofetil
5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Use
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End Use, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Use, 2023 to 2033
6.3.1. in Hospitals
6.3.2. in Adult Centers
6.3.3. in Ambulatory Surgical Centers
6.4. Y-o-Y Growth Trend Analysis By End Use, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End Use, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Treatment Type
8.2.3. By End Use
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment Type
8.3.3. By End Use
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment Type
9.2.3. By End Use
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment Type
9.3.3. By End Use
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Treatment Type
10.2.3. By End Use
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment Type
10.3.3. By End Use
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Treatment Type
11.2.3. By End Use
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment Type
11.3.3. By End Use
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Treatment Type
12.2.3. By End Use
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment Type
12.3.3. By End Use
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Treatment Type
13.2.3. By End Use
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment Type
13.3.3. By End Use
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Treatment Type
14.2.3. By End Use
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment Type
14.3.3. By End Use
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Treatment Type
15.1.2.2. By End Use
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Treatment Type
15.2.2.2. By End Use
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Treatment Type
15.3.2.2. By End Use
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Treatment Type
15.4.2.2. By End Use
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Treatment Type
15.5.2.2. By End Use
15.6. U.K.
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Treatment Type
15.6.2.2. By End Use
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Treatment Type
15.7.2.2. By End Use
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Treatment Type
15.8.2.2. By End Use
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Treatment Type
15.9.2.2. By End Use
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Treatment Type
15.10.2.2. By End Use
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Treatment Type
15.11.2.2. By End Use
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Treatment Type
15.12.2.2. By End Use
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Treatment Type
15.13.2.2. By End Use
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Treatment Type
15.14.2.2. By End Use
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Treatment Type
15.15.2.2. By End Use
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Treatment Type
15.16.2.2. By End Use
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Treatment Type
15.17.2.2. By End Use
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Treatment Type
15.18.2.2. By End Use
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Treatment Type
15.19.2.2. By End Use
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Treatment Type
15.20.2.2. By End Use
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Treatment Type
15.21.2.2. By End Use
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Treatment Type
15.22.2.2. By End Use
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Treatment Type
15.23.2.2. By End Use
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Treatment Type
16.3.3. By End Use
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Allosource
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Conatus Pharmaceuticals Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Digna Biotech
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. S.L.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Dompe Farmaceutici S.p.A.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Isogenis, Inc.
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. RedHill Biopharma Ltd.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Thompson Surgical
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Integra Life Sciences
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Baxter International Inc.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. XVIVO
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. VirTech Bio
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.13. Vital Therapies
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
17.1.14. HepaTx
17.1.14.1. Overview
17.1.14.2. Product Portfolio
17.1.14.3. Profitability by Market Segments
17.1.14.4. Sales Footprint
17.1.14.5. Strategy Overview
17.1.14.5.1. Marketing Strategy
17.1.15. Humedics
17.1.15.1. Overview
17.1.15.2. Product Portfolio
17.1.15.3. Profitability by Market Segments
17.1.15.4. Sales Footprint
17.1.15.5. Strategy Overview
17.1.15.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Liver Transplantation Market
